LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Avita Therapeutics Inc

Cerrado

3.36 2.44

Resumen

Variación precio

24h

Actual

Mínimo

3.27

Máximo

3.48

Métricas clave

By Trading Economics

Ingresos

-3.3M

-13M

Ventas

-1.4M

17M

BPA

-0.712

Margen de beneficios

-77.289

Empleados

260

EBITDA

4M

-8.1M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+98.78% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-17M

104M

Apertura anterior

0.92

Cierre anterior

3.36

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Avita Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 dic 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dic 2025, 23:51 UTC

Ganancias

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dic 2025, 23:39 UTC

Principales Movimientos del Mercado

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dic 2025, 21:40 UTC

Ganancias

Nike Sales Tick Up, But China Weakness Persists

18 dic 2025, 23:45 UTC

Charlas de Mercado

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dic 2025, 23:37 UTC

Charlas de Mercado
Ganancias

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dic 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dic 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dic 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dic 2025, 22:58 UTC

Adquisiciones, fusiones, absorciones

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dic 2025, 22:56 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dic 2025, 22:55 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:59 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 dic 2025, 21:35 UTC

Ganancias

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dic 2025, 21:31 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev Down 17% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q EPS 53c >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Apparel Rev $3.91B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Equipment Rev $550M >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q N Amer Rev $5.63B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Footwear Rev $7.66B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev $1.42B >NKE

Comparación entre iguales

Cambio de precio

Avita Therapeutics Inc previsión

Precio Objetivo

By TipRanks

98.78% repunte

Estimación a 12 Meses

Media 6.5 USD  98.78%

Máximo 11 USD

Mínimo 3 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avita Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.83 / 9.77Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat